AstraZeneca increases dividend
Quote from VATcal on 11/04/2024, 18:59AstraZeneca has announced a rise in its dividend after profits surged last year thanks to strong demand for its COVID-19 vaccine and cancer drugs.
The Anglo-Swedish drugmaker said its full-year dividend would rise by 7% to $3.10 per share.
The company said its net profit in 2023 rose to $6.4 billion from $3.9 billion a year earlier.
AstraZeneca's shares rose 1.5% in early trading on Thursday.
The company's COVID-19 vaccine, developed with the University of Oxford, has been a major source of revenue.
AstraZeneca has also benefited from the strong performance of its cancer drugs, such as Tagrisso for lung cancer.
The dividend increase comes despite concerns about the future of COVID-19 vaccine sales as the pandemic appears to be waning.
AstraZeneca said it was confident that its business would continue to grow in the coming years, driven by its portfolio of new drugs.
AstraZeneca has announced a rise in its dividend after profits surged last year thanks to strong demand for its COVID-19 vaccine and cancer drugs.
The Anglo-Swedish drugmaker said its full-year dividend would rise by 7% to $3.10 per share.
The company said its net profit in 2023 rose to $6.4 billion from $3.9 billion a year earlier.
AstraZeneca's shares rose 1.5% in early trading on Thursday.
The company's COVID-19 vaccine, developed with the University of Oxford, has been a major source of revenue.
AstraZeneca has also benefited from the strong performance of its cancer drugs, such as Tagrisso for lung cancer.
The dividend increase comes despite concerns about the future of COVID-19 vaccine sales as the pandemic appears to be waning.
AstraZeneca said it was confident that its business would continue to grow in the coming years, driven by its portfolio of new drugs.
